-
ASCO17: Days 4 and 5 Immunotherapy Highlights
Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical…
-
ASCO17: Day 3 Immunotherapy Highlights
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy…
-
ASCO17: Day 2 Immunotherapy Highlights
Day 2 at the 2017 annual meeting of the American Society of Clinical Oncology further highlighted immunotherapy's…
-
ASCO17: Day 1 Immunotherapy Highlights
Day 1 at the 2017 annual meeting of the American Society of Clinical Oncology demonstrated immunotherapy’s potential…
-
ASCO17: Exploring the Past, Present, and Future of Immunotherapy
Immunotherapy is poised to shine at ASCO17
-
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer
Durvalumab marks AstraZeneca’s first immunotherapy approval
-
NY-ESO-1 Identified as a Promising Vaccine Target in Ovarian Cancer Patients
New study reveals effectiveness of immunotherapy vaccine against aggressive ovarian tumors.
